15 Best Stocks Under $25 to Buy Now

Page 12 of 15

4. Roivant Sciences Ltd. (NASDAQ:ROIV)

Share Price as of December 29: $21.70

Number of Hedge Fund Holders: 54

Roivant Sciences Ltd. (NASDAQ:ROIV) ranks among the best stocks under $25 to buy now. Following the company’s analyst meeting on December 11, Leerink Partners boosted its price target for Roivant Sciences Ltd. (NASDAQ:ROIV) to $32 from $29, keeping an Outperform rating on the company’s shares. The firm highlighted lower estimated operational expenses in the years ahead than previously modeled, resulting in reduced expected losses and significant profitability beginning in fiscal year 2029.

By the end of 2028, Roivant’s “Next 36 Month vision” anticipates at least three commercial launches, four or more NDA/BLA submissions, no less than eight crucial readouts, and at least three proof-of-concept evaluations.

Roivant Sciences Ltd. (NASDAQ:ROIV) has also advanced the development schedules for its primary therapeutic candidates, including brepocitinib, with a New Drug Application filing for dermatomyositis slated in early 2026 along with a possible commercial launch in early 2027. Furthermore, the Phase III trial for brepocitinib in non-infectious uveitis has reached full enrollment ahead of time, with topline results expected in the second half of 2026.

Roivant Sciences Ltd. (NASDAQ:ROIV) is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes medicines and technologies. Its clinical product candidates include IMVT-1402, an antibody that targets the neonatal Fc receptor for the treatment of Graves’ disease and difficult-to-treat rheumatoid arthritis.

Page 12 of 15